Combining HO-1 inhibitors with emerging immunotherapies, including immune checkpoint inhibitors and CAR-T cell therapies, holds promise for amplifying anti-tumor immune responses and overcome resistance. The gene discussed is HMOX1; the disease is neoplasm.